Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab rezetecan + adebrelimab + capecitabine for HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2600134798Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan, adebrelimab and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Progression-Free Survival, Duration of Response and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanadebrelimabcapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600134798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134798.